Lau G, Abou-Alfa GK, Cheng AL, Sukeepaisarnjaroen W, et al. Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. J Hepatol 2024 Jul 30:S0168-8278(24)02424-3. doi: 10.1016/j.jhep.2024.
PMID: 39089633